Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatmentKoji Haratani, Kazuhiko Nakagawa, Hidetoshi Hayashi et al.|Annals of Oncology|2017Cited by 294
B7-H3 Negatively Modulates CTL-Mediated Cancer ImmunityKimio Yonesaka, Kazuhiko Nakagawa, Shiki Takamura et al.|Clinical Cancer Research|2018Cited by 169
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary SiteHidetoshi Hayashi, Kazuhiko Nakagawa, Takayasu Kurata et al.|Journal of Clinical Oncology|2019Cited by 168
Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung CancerJunko Tanizaki, Kazuhiko Nakagawa, Isamu Okamoto et al.|Clinical Cancer Research|2012Cited by 156
Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary SiteHidetoshi Hayashi, Kazuhiko Nakagawa, Yuichi Takiguchi et al.|JAMA Oncology|2020Cited by 119